Want to see HK:1541 full AI Analyst Report?

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Revenue

3 Followers

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had a revenue of 37.25M in the quarter ending Jun 30, 2026, with -67.42%. This bring the company's revenue in the last twelve months to 151.57M, Increased -4.27%. In the fiscal year ending Dec 31, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had annual revenue of 150.30M with 102.70% growth.

Revenue (ttm)

151.57M

Revenue Growth

28.93%

P/S Ratio

9.76

Revenue/Employee

HK$744,063

Employees

202

Market Cap

HK$1.47B

Revenue Chart

Revenue History

Fiscal End Date	Revenue	Change	Growth
Dec 31, 2025	150.30M	76.15M	+102.70%
Dec 31, 2024	74.15M	73.76M	+19,109.59%
Dec 31, 2023	386.00K	-5.30M	-93.22%
Dec 31, 2022	5.69M	-8.12M	-58.79%
Dec 31, 2021	13.81M	―	―